ERBB2 and neoplasm: Currently, there are several ongoing clinical trials evaluating prevalence of HER2 alterations and the benefit of targeting HER2 in different tumor types (eg, ClinicalTrials.gov identifiers: NCT02465060, NCT02675829, NCT02091141, NCT02693535).